

1 **Single-cell Transcriptome Analysis Indicates New Potential Regulation Mechanism of**  
2 **ACE2 and NPs signaling among heart failure patients infected with SARS-CoV-2**

3  
4 Dachun Xu<sup>1\*</sup>, Mengqiu Ma<sup>1\*</sup>, Yanhua Xu<sup>1\*</sup>, Yang Su<sup>1\*</sup>, Sang-Bing Ong<sup>2</sup>,

5 Xingdong Hu<sup>3</sup>, Min Chai<sup>4</sup>, Maojun Zhao<sup>5</sup>, Hong Li<sup>6</sup>, Xiaojiang Xu<sup>7#</sup>

6  
7 <sup>1</sup>Department of Cardiology, Shanghai Tenth People's Hospital, Tongji University School of  
8 Medicine, 1239 Siping Road, Shanghai, 200072, China. <sup>2</sup>Department of Medicine and  
9 Therapeutics, Chinese University of Hong Kong, Hongkong, China. <sup>3</sup>Department of Critical  
10 Care Medicine, The third people's Hospital of Guizhou Province, Guiyang, China. <sup>4</sup>Department  
11 of Critical Care Medicine, Ezhou Central Hospital, Ezhou, China. <sup>5</sup>Emergency department,  
12 The First People Hospital's of Guiyang, Guiyang, Guizhou, China. <sup>6</sup> IID, NIEHS, National  
13 Institutes of Health, Research Triangle Park, NC, 27709, USA. <sup>7</sup>Integrative Bioinformatics,  
14 ESCBL, NIEHS, National Institutes of Health, Research Triangle Park, NC, 27709, USA

15  
16 \* Dachun Xu, Mengqiu Ma, Yanhua Xu and Yang Su contributed equally to this work.

17 # Correspondence: Xiaojiang Xu, Ph.D. Email: [xiaojiang.xu@nih.gov](mailto:xiaojiang.xu@nih.gov).

18  
19 **Abstract**

**NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.**

20 The coronavirus disease 2019 (COVID-19) has resulted in high morbidity and mortality  
21 worldwide since December 2019. Recent studies showed that patients with previous heart  
22 disease, especially heart failure (HF), whose plasma Natriuretic Peptides (NPs) concentrations  
23 are higher, were more susceptible to SARS-CoV-2 infection. In this study, we retrospectively  
24 analyzed single-center case series of 91 patients with COVID-19 in China. 46 (50.5%) patients  
25 exhibited cardiac dysfunction as indicated by elevated Natriuretic Peptides B (BNP) levels.  
26 Moreover, the results indicate that patients with cardiac dysfunction had higher mortality than  
27 those without cardiac dysfunction. Nonetheless, it remains unclear as to how the virus infects  
28 the heart, especially in HF patients and why a higher level of BNP in the heart dampen  
29 inflammation. Angiotensin-converting enzyme 2 (ACE2), the critical host cellular receptor of  
30 SARS-CoV-2, expresses in different organs. Still, its cellular distribution in the human heart,  
31 especially in patients with HF remains unclear. Thus, we investigated ACE2 gene expression  
32 pattern in single-cell RNA sequence (scRNA-seq) data of hearts from normal adults versus  
33 patients with HF. Our results indicate that ACE2 is predominantly enriched in cardiomyocytes  
34 (CMs), endothelial cells, fibroblasts and smooth muscle cells in normal heart. Not only ACE2+  
35 CMs, but also expression of ACE2 are significantly boosted in CMs of patients with HF. Also,  
36 genes related to virus entry, virus replication and suppression of IFN- $\gamma$  signaling besides ACE2  
37 were up-regulated in HF patient, mainly in CMs, indicating the higher susceptibility to SARS-  
38 CoV-2 infection. Interestingly, NPs are significantly up-regulated in ACE2-positive (ACE2+)  
39 ventricular myocytes and share the upstream transcription factor. ACE2 and NPs can form a  
40 negative feedback loop with protective effects. But it maybe turns into a positive feedback loop  
41 by virus and ineffective NPs, which lead to severe prognosis. In summary, the increased

42 expression of ACE2, NPs during HF predisposes to SARS-CoV-2 infection. Modulating the  
43 levels of ACE2, NPs therefore may potentially be a novel therapeutic target to prevent the  
44 SARS-CoV-2 infection.

45 **Running title:** scRNA-seq and ACE2 and NPs signaling in COVID-19 with heart failure

46 **Keywords:** COVID-19, SARS-CoV-2, Heart failure, Cardiac dysfunction, Angiotensin  
47 converting enzyme 2, Single-cell sequence

## 48 **Introduction**

49 A novel disease termed Coronavirus Disease 2019 (COVID-19) caused by severe acute  
50 respiratory syndrome, coronavirus 2(SARS-CoV-2) broke out in December 2019<sup>1</sup>. The virus  
51 has spread worldwide and classified as a pandemic in 2020. As of April 2020, more than 30  
52 million cases of COVID-19 and more than 200,000 deaths have been reported worldwide<sup>2</sup>.  
53 Besides respiratory illness, the viral infection causes a series of symptoms related to myocardial  
54 injury, including cardiac dysfunction<sup>1, 3, 4</sup>. Recent clinical studies have found that the elderly  
55 and individuals with underlying comorbidities, including cardiovascular diseases such as  
56 hypertension (HTN) and coronary heart disease (CAD) are more susceptible to SARS-CoV-2  
57 with worse prognosis<sup>5, 6</sup>. Cardiac injury has also been found to be a common condition among  
58 hospitalized patients with COVID-19 and is associated with a higher risk of in-hospital  
59 mortality<sup>5</sup>.

60 Single-cell RNA sequencing has shown that the SARS-CoV-2 entry receptor, angiotensin-  
61 converting enzyme 2 (ACE2) is highly expressed in the nasal, kidney, endothelium, testis, and  
62 heart<sup>7-12</sup>. Zou *et al.* reported that cardiomyocytes (CMs) contained ACE2 positive cells, thus

63 raising the possibility of the myocardium being infected with SARS-CoV-2<sup>9</sup>. ACE2 functions  
64 to convert angiotensin II (Ang II) into angiotensin1-7 (Ang1-7) thus preserving ejection  
65 fraction in patients with HF<sup>13</sup>. As such, patients with underlying cardiovascular disorders such  
66 as HF are more susceptible to be infected by the virus and their mortality rates are higher than  
67 compared to normal patients resulting from increased ACE2<sup>14</sup>. Nonetheless, at the single cell  
68 level, nothing much is known about the underlying mechanism as to why the failing heart is  
69 more vulnerable to the virus compared with a normal heart.

70 Our present study retrospectively analyzed a single-center case series in Ezhou, China. The  
71 results show that cardiac dysfunction (BNP $\geq$ 100 pg/mL) in patients infected with SARS-CoV-  
72 2 is associated with higher mortality. We then applied single-cell RNA sequencing (scRNA-  
73 seq) to hearts from the normal adults versus patients with failing heart to elucidate the potential  
74 mechanisms of acute myocardial injury caused by SARS-CoV-2 infection. ACE2 transcript  
75 was detected in all types of cells in heart, including cardiomyocytes (CMs), endothelial,  
76 fibroblasts and smooth muscle cells and immune cells. A type of abnormal CMs (CM4) was  
77 identified specifically in HF patients. Genes related to virus entry, virus replication and  
78 suppression of IFN- $\gamma$  signaling besides ACE2 were up-regulated in HF patient. Interestingly,  
79 ACE2-positive (ACE2+) ventricular myocytes expressed high NPs. We demonstrated that the  
80 increased expression of ACE2, BNP and ANP during heart failure predisposes to SARS-CoV-  
81 2 infection. ACE2, BNP and ANP therefore could be a novel therapeutic target to prevent the  
82 SARS-CoV-2 infection.

## 83 **Materials and Methods**

## 84 **Study Participants**

85 Patients admitted to Ezhou Central Hospital, Ezhou, China with laboratory-confirmed COVID-  
86 19 were included in this retrospective cohort study, which was conducted from January 25,  
87 2020, to March 15, 2020. The patients with COVID-19 enrolled in this study were diagnosed  
88 according to World Health Organization interim guidance <sup>15</sup>. The cases without a BNP  
89 measurement were excluded. This study was approved by the National Health Commission of  
90 China and Shanghai Tenth People's Hospital, Tongji University School of Medicine (Shanghai,  
91 China). Written informed consent was waived by the ethics committee of the designated  
92 hospital for patients with emerging infectious diseases.

## 93 **Data Collection**

94 The demographic characteristics, clinical data (comorbidities, laboratory findings, and  
95 outcomes), laboratory findings for participants during hospitalization were collected from  
96 electronic medical records. Cardiac biomarkers measured on admission were collected,  
97 including TNI, CK-MB, and BNP. All data were independently reviewed and entered the  
98 computer database by three analysts. Patients were categorized according to the BNP. Acute  
99 heart failure (HF) was defined as blood levels of BNP above 100 pg/ml, regardless of  
100 cardiovascular disease history and new abnormalities in electrocardiography and  
101 echocardiography. The clinical outcomes (i.e., discharges and mortality) were monitored up to  
102 March 15, 2020.

103 PCR-Fluorescence probing based kit ( Novel Coronavirus(2019-nCoV) Nucleic Acid  
104 Diagnostic Kit, Sansure Biotech, China) was used to extract nucleic acids from clinical sample

105 and detect the ORF1ab gene (nCovORF1ab) and the N gene (nCoV-NP) according to the  
106 manufacturer's instructions. An infection was considered laboratory-confirmed if the  
107 nCovORF1ab and nCoV-NP tests both showed positive results.

## 108 **Statistical Analysis**

109 Descriptive statistics were obtained for all study variables. Continuous data were expressed as  
110 mean (SD) or median (interquartile range [IQR]) values. Categorical data were expressed as  
111 proportions. All continuous variables were compared using the t-test or the Mann-Whitney U-  
112 test if appropriate. In contrast, categorical variables were analyzed for the study outcome by  
113 Fisher exact test or  $\chi^2$  test. The Pearson correlation coefficient and Spearman rank correlation  
114 coefficient were used for linear correlation analysis. Survival analysis between patients with  
115 BNP<100 pg/mL and  $\geq$ 100 pg/mL was conducted by the Kaplan-Meier estimate with p-value  
116 generated by the log-rank test. Data were analyzed using SPSS version 25.0 (IBM Corp) or  
117 Graphpad Prism 8.0.1 (GraphPad Software, San Diego, CA). For all the statistical analyses, 2-  
118 sided  $p < 0.05$  was considered significant.

## 119 **scRNA-seq analysis**

### 120 **Data Sources**

121 Adult human heart scRNA-seq datasets were obtained from Gene Expression Omnibus (GEO)  
122 under accession codes GSE109816 and GSE121893. Shortly, samples from fourteen healthy  
123 donors, six HF patients who were undergoing heart transplantation and two patients with heart  
124 failure before and after LV assist device (LVAD) treatment were obtained. The range of donor  
125 ages was 21-52 year, with a median age of 45.5 year.

126 **Sequencing data processing**

127 The processed read count matrix was retrieved from existing sources based on previously  
128 published data as specified explicitly in the reference. Briefly, Raw reads were processed using  
129 the Perl pipeline script supplied by Takara.

130 **Single-cell clustering and identify cell types**

131 The processed read count matrix was imported into R (Version 3.6.2) and converted to a Seurat  
132 object using the Seurat R package (Version 3.1.2). Cells that had over 75% UMIs is derived  
133 from the mitochondrial genome were discarded. For the remaining cells, gene expression  
134 matrices were normalized to total cellular read count using negative binomial regression  
135 method implemented in Seurat *SCTransform* function. Cell-cycle scores were calculated using  
136 Seurat *CellCycleScoring* function. The Seurat *RunPCA* functions were performed to calculate  
137 principal components (PCs). We further corrected the batch effect using Harmony because  
138 batch effects among the human heart samples were observed. The *RunUMAP* function with  
139 default setting was applied to visualize the first 35 Harmony aligned coordinates. The  
140 *FindClusters* function with resolution=0.2 parameter was carried out to cluster cells into  
141 different groups. Canonical marker genes were applied to annotate cell clusters into known  
142 biological cell types. Monocle 3<sup>16</sup> as used to perform trajectory and pseudotime analysis.

143 **Identification of differential expression genes (DEG)**

144 To identify DEG between two groups, we applied the Seurat *FindMarkers* function with the  
145 default parameter of method “MAST” and cells ID from each defined group (e.g. ACE2+ cells  
146 vs ACE2- cells in CM1) as input.

147 **Gene function analysis**

148 GSEA (Version 4.03) was used to perform gene ontology (GO) term and pathway enrichment  
149 analysis with the Molecular Signatures Database (MSigDB, C2 and C5, Version 7.01).

150

## 151 **Results**

### 152 **Clinical Characteristics**

153 The median age of these 91 SARS-CoV-2-infected patients was 66 years (range, 27-89 years),  
154 and 54 (59.3%) were male. 46 patients (50.5%) were divided into elevated BNP group ( $\geq 100$   
155 pg/mL) with median (IQR) level of 299.5 [180.0, 548.0] pg/mL. HF patients have increased  
156 ANP and BNP plasma concentrations, which correlates with cardiovascular disease severity.  
157 BNP is widely recognized as a diagnostic marker and therapeutic hormone in clinical practice<sup>17</sup>.  
158 Patients with higher BNP were older (median age, 79 [44-89] years vs. 62 [27-79] years;  
159  $p < 0.0001$ ). In the higher BNP group, levels of white blood cell ( $13.05 [6.76, 18.13] 10^9/L$ )  
160 and neutrophil ( $11.88 [4.83, 16.93] 10^9/L$ ) were significantly higher, while the level of  
161 lymphocyte ( $0.50 [0.27, 0.78] 10^9/L$ ) was significantly lower. Generally, organ impairment  
162 was significantly more severe in higher BNP group, including worse liver function indicated  
163 by aspartate transaminase (AST,  $41.5 [29.0, 64.0]$ , U/L), direct bilirubin ( $6.6 [4.0, 13.2]$ ,  
164  $\mu\text{mol/L}$ ), and lactate dehydrogenase (LDH,  $407.0 [288.0, 599.0]$ , U/L) and worse renal function  
165 indicated by eGFR ( $86.5 \pm 44.5$ , mL/(min\*1.73m<sup>2</sup>) and blood urea nitrogen (BUN,  $9.0 [5.2,$   
166  $15.9]$ , mmol/L). Cardiac injury indicated by troponin I ( $0.05 [0.03, 0.25]$ , ng/mL) was  
167 significant in higher BNP group. Electrolytes disturbance with elevated potassium ( $4.19 [3.64,$   
168  $4.70]$ , mmol/L) and decreased calcium ( $1.97 \pm 0.18$ , mmol/L) level were observed in higher  
169 BNP group. Among the coagulation profiles, prothrombin time (PT,  $13.9 [12.8, 16.7]$ , s) was

170 prolonged and D-dimer (6.96 [3.25, 24.2],  $\mu\text{g/mL}$ ) level was significantly raised. Inflammatory  
171 biomarkers, as procalcitonin (1.01 [0.39, 3.51],  $\text{ng/mL}$ ) and hsCRP (18.00 [13.45, 21.50],  
172  $\text{mg/L}$ ), showed a more intense infection in higher BNP group. Blood gas analysis was  
173 comparable between groups. Noteworthy, mortality (58.70%) was significantly higher in  
174 patients with higher BNP. (Shown in Table 1)


175

### 176 **Relationships between BNP level and clinical assessments**

177 Although blood gas analysis was comparable between groups, patients with higher BNP level  
178 had a higher incidence of respiratory failure (RF, 31.43%,  $p=0.0064$ ) (Fig. 1A). BNP level was  
179 positively correlated with procalcitonin ( $r=0.6365$ ,  $p<0.0001$ ,  $R^2=0.38$ ), neutrophil ( $r=0.5263$ ,  
180  $p<0.0001$ ,  $R^2=0.25$ ), and D-dimer ( $r=0.5824$ ,  $p<0.0001$ ,  $R^2=0.33$ ), but negatively correlated  
181 with lymphocyte ( $r=-0.5585$ ,  $p<0.0001$ ,  $R^2=0.29$ ). (Fig. 1B-E). Of note, mortality was  
182 significantly increased through a 30-day follow-up in the higher BNP group. (Log-rank  
183  $p<0.0001$ ) (Fig. 1F).

### 184 **Integrated analysis of normal and HF conditions at single-cell resolution**

185 To detect the discrepancy between normal and heart failure patients, the schematic of the  
186 study was performed according to the description of Wang *et al*<sup>18</sup>. Shortly, the samples of  
187 fourteen healthy donors (hereinafter called normal) were obtained. Six HF patients were  
188 undergoing heart transplantation and two patients with HF before and after left ventricle  
189 assist device (LVAD) treatment (hereinafter called patient). 9767 out of 9994 cells from  
190 normal and 4931 out of 4933 cells from patient passed standard quality control and retained



191


192 **Figure 1. Relationships between BNP level and clinical assessments.**

193 **A**, the bars were constituted by percentages of non-respiratory failure (RF), type 1 RF, and  
 194 type 2 RF patients. There were 79.17% patients with non-RF, 20.83% RF1, and no RF2 in  
 195 BNP<100 pg/mL group, while 68.57% non-RF, 8.57% RF1, and 22.86% RF2 in BNP≥100  
 196 pg/mL group. The proportion of groups was significantly different ( $p=0.0064$ ). **B, C, D and**  
 197 **E**, the procalcitonin, neutrophil, and D-dimer level presented a significantly positive  
 198 correlation with BNP level after log transformation, and lymphocyte presented a negative  
 199 correlation. **F**, K-M estimate showed the mortality in BNP≥100 pg/mL (dash line) group  
 200 (58.7%) was significantly higher compared with BNP<100 pg/mL (solid line) group (11.11%)  
 201 after a 30-day follow-up.

202 for subsequent analyses. On average, we detected 1649 and 1904 genes in individual cell from  
 203 normal and patient, respectively. Then, we performed uniform manifold approximation and  
 204 projection (UMAP) and clustering analysis and grouped the entire population into nine clusters

205 (Fig. 2A). Dot plot showed the gene expression of known markers for nine clusters, which  
206 include: 1) endothelial cells (Cluster 1, PECAM1 and VWF); 2) fibroblasts (Cluster 5, LUM  
207 and DCN); 3) smooth muscle cells (Cluster 3, MYH11); 4) NK-T/ monocytes (Cluster 6, CD3G  
208 and CD163); 5) granulocytes (Cluster 9, HP, ITLN1); 6) CM2 and 3 subsets (Clusters 2/4/8,  
209 MYH6 and NPPA); 7) CM1 and 4 subsets (Clusters 0 and 7, MYH7 and MYL2) (Fig. 2B).  
210 Then, UMAP for an individual sample was separately plotted side by side and exhibited the  
211 differential distribution of subsets between normal and HF patients. As shown in Fig. 2C, all  
212 nine subsets were detected in both normal and patient group. However, different cell type  
213 displayed various cell number percentage change between normal and patients. CM1  
214 percentage dramatically decreased from 39.65% to 7.12% ( $p < 0.0001$ ), while the percentage of  
215 CM4 significantly increased from 0.03% to 7.81% ( $p < 0.0001$ ). CM2 and CM3 also increased  
216 from 17.70% to 20.08% ( $p < 0.0001$ ) and 8.27% to 11.56% ( $p = 0.0005$ ) respectively.

217 Cell numbers of endothelial and fibroblasts were also increased from 16.79% to  
218 24.07% ( $p < 0.0001$ ) and 4.53% to 10.97% ( $p = 0.0018$ ) after HF, respectively (Fig. 2D). Their  
219 cell percentage changes during HF suggest different cell type has a specific response, especially  
220 in cardiomyocytes, endothelial cells and fibroblasts. For each cluster, we calculated the cluster-  
221 specific expression genes (marker genes). Left ventricle (LV) marker genes MYL2 and MYL3  
222 were highly expressed in CM1 and 4; so, we termed the subsets CM1 and 4 as LV  
223 cardiomyocytes. Left atrium (LA) marker genes MYH6 and MYH7 are highly expressed in  
224 CM2 and 3, they were termed as LA cardiomyocytes<sup>19</sup>.



225

226 **Figure 2. Integrated analysis of normal and HF conditions at single-cell resolution**

227 A, UMAP clustering of 14698 cells isolated from normal and heart failure patients. Each dot  
 228 represents a single cell. Cell type was annotated by the expression of known marker genes. B,  
 229 Dot plotting showing gene signature among different clusters, the shadings denotes average  
 230 expression levels and the sizes of dots denote fractional expression. C, Split views show the 9  
 231 subsets in normal and patient group. D, The percentage of cell number for different cell types  
 232 in normal and patient group.

233 **CMS and Non-CMs (NCMs) shows different characteristics between normal and HF**

234 We compared genes expression of atrial monocytes (CM2&3) and NCMs between normal and  
 235 patients. We observed that GO term viral genes expression was up-regulated at all atrial

236 monocytes and NCMs in HF (Supplementary Fig. S1A-F). We previously reported that all  
237 atrial monocytes and NCMs have high percentage of ACE2+ cells. These results suggested that  
238 all kind of cell type in heart are liable to SARS-CoV-2. In addition, for atrial monocytes of  
239 failing heart, GO results showed us that genes related to mitochondrial protein complex and  
240 other related to ATP synthesis are up-regulated while genes related to inflammatory response,  
241 leukocyte migration, response to interferon-gamma and others related to defend against  
242 pathogens are downregulated, indicating failing atrial monocytes is characterized with lower  
243 resistance to virus (Supplementary Fig. S1A). From these results, CMs show different  
244 characteristics from normal and failing heart, indicating different role in virus infection.

245 To further determine the relationship between CM1 and CM4, we performed trajectories  
246 analysis of the integrated clusters to show the pseudotime of CMs and NCMs. Trajectory and  
247 pseudotime results indicated CM4 originated from CM1 (Fig. 3A), which is consistent with  
248 our speculation that CM4 is a type of abnormal CM after HF. Then we conducted GSEA  
249 analysis (GO and Pathway) on DEG between CM4 and CM1. GO term viral gene expression  
250 and pathway influenza infection, infectious diseases and HIV infection were upregulated in  
251 CM4 (Fig. 3B and C); but GO term response to virus, defense response to virus, response to  
252 interferon gamma and innate immune response, and pathway the adaptive immune response,  
253 interferon signaling and interferon-alpha-beta-gamma signaling was down-regulated  
254 significantly in CM4 (Fig. 3D and 3E). In summary, these results indicate CM4 is more  
255 vulnerable to virus than CM1.


256 **CMs and NCMs have different ACE2 expression pattern**

257 We further investigated ACE2+ cells frequency change of CMs and NCMs in the failing heart  
258 by comparing them with normal hearts. Fig. 4A showed that the distribution of ACE2+ cells  
259 during HF shifted. Additionally, we calculated the ACE2+ cells frequency across distinct cell  
260 subsets of CMs and NCMs. The frequency of ACE2+ cells increased significantly in three of  
261 four CMs in HF patients, especially in CM1 and CM4. The proportions rose from 5.55% to  
262 31.05% ( $p<0.0001$ ) and from 0% to 7.01% ( $p<0.0001$ ) respectively. The frequency of ACE2+  
263 cells in CM3 significantly increased from 6.19% to 13.16% ( $p<0.0001$ ) , but CM2 didn't  
264 change (from 5.55% to 5.66%,  $p>0.05$ ) (Fig. 4B).

265 In summary, our scRNA-seq results demonstrated that ACE2+ CMs dramatically increased  
266 during HF, which suggests that HF patients are more susceptible to SARS-CoV-2 than regular  
267 patients. Also, ventricular myocytes had higher percentage of ACE2+ cells than that at atrial  
268 myocytes, which indicate that they have different response to SARS-CoV-2. ACE2+ cells  
269 percentage in NCMs showed a various pattern, for example, the percentage of ACE2+ cells in  
270 fibroblasts ( $p<0.0001$ ) and smooth muscle cells ( $p=0.0104$ ) were decreased. The frequency  
271 of ACE2+ cells in immune subsets NK-T Cell/Monocytes and granulocytes increased from  
272 3.77% to 4.85% ( $p>0.05$ ) , 2.04% to 5.83% ( $p>0.05$ ) , respectively.

### 273 **Virus infection-related genes are upregulated in HF patients compared with normal**

274 First, we focused on gene expression dynamics of SARS-CoV-2 entry receptor, ACE2. To  
275 further examine the potential role of ACE2+ cells in myocardium infected by SARS-CoV-2,  
276 we separated each cell types into two sub-groups (ACE2 positive and ACE2 negative) and  
277 called DEGs between these two groups. In ventricular myocytes, *NPPB*, the gene coding




278

279 **Figure 3. CM4 shows different characteristics with CM1**

280 **A**, Pseudotime analysis of the nine clusters, the color from purple to yellow denote the different  
281 developing stage, and the simultaneous principal curve indicates the pseudo-time stage. **B, C**,  
282 GSEA analysis revealed that significant enrichment of GO and pathways for DEGs of CM4  
283 and CM1. **D**, GO enrichment showing GO terms of increased viral gene expression, decreased  
284 adaptive immune response and defense response to virus. **E**, Influenza infection signaling  
285 pathway is up-regulated, both interferon-alpha-beta signaling and interferon-gamma signaling  
286 are down-regulated

287 BNP and *NPPA* (the gene coding ANP) is the top two upregulated genes with fold change >1.8  
288 in ACE2+ cells. Previous studies reported that ACE2, ANP, BNP, TnT and TnI could make a  
289 feedback loop to reserve ejection fraction in HF<sup>20-23</sup> patients . We further studied these ejection  
290 fraction preservation genes. Interestingly, we found out that most of them not only are  
291 significantly upregulated during HF, but also upregulated in ACE2+ CMs cells (Fig. 4C). To  
292 denote their relationship, we built gene regulatory network (GRN) using string (string-db.org).  
293 GRN showed that *ACE2*, *NPPA*, *NPPB*, *TNNT1*, *TNNT 2* and *TNNT3* were well connected (Fig.  
294 4D). Based on these co-incidence results, we speculate that these ejection fraction preservation  
295 genes may affect virus infection.

296 Next, we studied the gene expression dynamics of *ACE2*, *NPPA* and *NPPB* in CMs and  
297 NCMs during HF. Both *NPPB* and *NPPA* were co-expressed with *ACE2* and significantly up-  
298 regulated in CMs during HF (Fig. 5A, 5B). *NPPB* and *NPPA* have different expression pattern.  
299 *NPPA* has high expression at atrial myocytes (CM2, 3) and NCMs in normal heart and was  
300 significantly upregulated at all CMs (Fig. 5B). *NPPB* has relatively low, but specific  
301 expression at atrial myocytes (CM2, 3) in normal heart and significantly upregulated



302

303 **Figure 4. CMs and NCMs have different ACE2 expression pattern**

304 **A**, UMAP of the CMs and NCMs subsets in normal and HF patients. **B**, Frequency of ACE2+

305 cells in different cell types. **C**, Gene expression pattern of virus infection-related genes in


306 different subsets of CMs during HF. **D**, Gene regulatory network of ACE2, NPPA, NPPB and

307 TNNT1,2,3.

308 at all CMs except CM4(Fig. 5A). To our surprise, *NPPB* is barely expressed at CM4. Then, we

309 extended our research to other virus infection-related genes, which involved in virus entry

310 (BSG, CAV2, CHMP3, CHMP5, STOML2), cysteine proteases cathepsins (CSTB, CSTD,  
 311 CSTL), virus replication (AKAP9, RDX, MTCH1) and suppression of IFN- $\gamma$  signaling  
 312 ( LARP1, RBX1 and TIMM8B) (Fig. 5C-F). Genes contributed to virus entry (Fig. 5C,5D,  
 313 Supplementary Fig. S2A, S2B), virus replication (Fig. 5F) and suppression of IFN- $\gamma$  signaling  
 314 (Fig. 5E) were up-regulated at CMs during HF. SARS-CoV-2 entry host CMs requires ACE2  
 315 spike protein and protease. It was reported that SARS-CoV-2 can use ACE2 and cellular  
 316 protease TMPRSS2 for entry into host cells<sup>24</sup>.



317


318 **Figure 5. Virus related genes are upregulated in HF patients compared with normal**

319 **A**, Expression level of ACE2 (red dots), NPPB (green dots) in different clusters, overlapping  
320 is shown in the right panel, and the co-expression is shown in yellow dots. Violin plots of the  
321 distribution of NPPB between normal and HF patients in different subsets. **B**, Expression level  
322 of ACE2 (red dot), NPPA (green dot) in different subsets, overlapping is shown in the right  
323 panel, and the co-expression is shown in yellow dots. Violin plots of the distribution of NPPA  
324 between normal and HF patients in different subsets. **C**, Violin plots of the distribution of genes  
325 (from top to bottom BSG, CAV2, CHMP3) related to viral infection. **D**, Violin plots of the  
326 gene expression pattern of CST B/L. **E**, Violin plots of the distribution of genes  
327 (from top to bottom AKAP9, RDX, MTCH1) related to IFN- $\gamma$  signaling pathway. **F**, Violin  
328 plots of the distribution of genes (from top to bottom LARP1, RBX1, TIMM8B) on viral  
329 replication.

330 Surprisingly, we barely detected expression of TMPRSS2 in both normal and HF samples  
331 (Supplementary Fig. S2C). It was reported that inhibiting both proteases plays an indispensable  
332 role in blockade of SARS-CoV viral entry<sup>25</sup> and SARS-CoV-2 can use them to prime in cell  
333 lines<sup>24</sup>. So, we investigated gene expression dynamics of the endosomal cysteine proteases  
334 cathepsins and found out that CTSB, CTSD and CTSL were up-regulated significantly in CMs  
335 during HF (Fig. 5D). We speculate that virus mainly uses ACE2-CTSB/L axis entry into host  
336 cells. The above results imply that Heart dysfunction or HF patients are more vulnerable to  
337 SARS-CoV-2.

338 Thrombosis is the main cause accentuate illness in severe patients<sup>26</sup>. Tissue factor

339 (TF/CD142) activation cause thrombus formation on atherosclerotic plaques coded by F3<sup>27</sup>.  
 340 We investigated the expression dynamics of genes related to signal blood clotting. F3 was co-  
 341 expressed with ACE2 and significantly up-regulated in CM3 and CM1 during HF  
 342 (Supplementary Fig. S2D) which indicated that HF patient may possess increased risk of blood  
 343 clot.



344

345 **Figure 6. Characteristics of ACE2-positive ventricular and atrial myocytes.**


346 **A**, GO analysis revealed that significant enrichment of biological pathways from comparison  
347 of ACE2+ ventricular myocytes and ACE2- ventricular myocytes. **B**, GO analysis revealed that  
348 significant enrichment of biological pathways from comparison of ACE2+ atrial myocytes and  
349 ACE2- atrial myocytes. **C**, GO plots showing GO terms of increased energy derivation by  
350 oxidation of organic compounds (left), decreased interferon gamma mediated signaling  
351 pathway (median) and down-regulated defense response to virus (right). **D**, GO enrichment  
352 plots showing GO terms of increased mitochondrial envelope (left), decreased innate immune  
353 response (median) and down-regulated innate immune response (right). The NES and false  
354 discovery rate (FDR) were showed in panel.

### 355 **Characteristics of ACE2 positive ventricular and atrial myocytes**

356 We conducted GSEA analysis on DEGs of cells between ACE2+ and ACE2- in ventricular  
357 myocytes (CM1 and CM4) (Fig.6A, Supplementary Fig. S3A). GO term associated with energy  
358 consumption (Fig. 6A), energy derivation by oxidation (Fig. 6C), and pathway influenza  
359 infection (Supplementary Fig. S3C) and infectious disease (Fig. S3A) were positively enriched  
360 in ACE2+ cells. In contrast, GO terms interferon gamma mediated signaling pathway, defense  
361 response to virus and pathway interferon-alpha\_beta signaling and interferon signaling were  
362 negatively enriched in ACE2+ cells (Fig. 6C, Supplementary Fig. S3C).

363 Furthermore, we performed GSEA analysis on DEGs of cells between ACE2+ and ACE2-  
364 in atrial myocytes (CM2 and CM3) (Fig. 6B, Supplementary Fig. S3B). GO terms associated  
365 with energy consumption, mitochondrial envelope, ATP synthesis coupled electron transport,  
366 oxidative phosphorylation and pathway cardiac muscle contraction, respiratory electron  
367 transport were positively enriched (Fig. 6B, 6C, Supplementary Fig. S3B, S3C). On contrary,

368 GO terms and pathways associated with innate immune response, response to interferon  
 369 gamma, interferon gamma signaling and interferon-alpha\_beta signaling were negatively  
 370 enriched which shared the same trend as ventricular myocytes (Fig. 6D, Supplementary Fig.  
 371 S3D). ACE2+ CMs are characterized with capacity of reduced immuno-regulatory effect and  
 372 have more energy consumption compared with ACE2- CMs. Moreover, we also identified  
 373 DEGs between ACE2+ NCMs and ACE2- NCMs and GSEA analysis (Supplementary Fig. S4).  
 374 Interestingly, pathways associated with infectious disease was positively enriched in NCMs,  
 375 except for NK-T Cells/Monocytes. GO terms associated with mitochondrial matrix and ATP  
 376 synthesis were positively enriched in smooth muscle cells, NK-T Cells/Monocytes and  
 377 fibroblasts, which is consistent with observation at CMs. GO term associated with muscle  
 378 structure and function (Supplementary Fig. S4A, S4E) and leukocyte mediated immunity were  
 379 negatively enriched in ACE2+ cells of smooth muscle



380  
 381 **Figure 7. Conceptual Schematic diagram highlighting the central role of SARS-CoV-2**  
 382 **and the natriuretic peptide, Renin-Angiotensin-Aldosterone system in the potentially**

383 **deleterious (red) and protective (purple) effects.**

384 **A**, scRNA-seq analysis detected the down-regulated IFN related genes and up-regulated viral  
385 infection related genes during HF, which imply reduced anti-viral signaling. **B**, Schematic  
386 diagram showed the process during heart failure in the early stage and later stage noted in  
387 purple and orange, respectively. **C**, The process under virus infection was noted in red to  
388 speculate the underlying relationship for the higher susceptibility and worse prognosis in HF.  
389 Oval circles and bars indicated the potential drug and targets.

390 cells, fibroblasts, and endothelial cells (Supplementary Fig. S4B). GO term associated with  
391 viral expression is positively enriched in ACE2+ granulocytes, while GO term associated with  
392 immunocyte mediated immunity is negatively enriched in ACE2+ granulocytes and ACE2+  
393 NK-T Cells/Monocytes which indicates their dysfunctions to fight against pathogens  
394 (Supplementary Fig. S4C, S4D).

395

## 396 **Discussion**

397 Our clinical data indicates that patients with high BNP ( $\geq 100$  pg/mL) were more likely to have  
398 complications such as liver and kidney injury resulting in a poor prognosis. This is the first  
399 study, at single-cell level, to systematically investigate ACE2 and other virus entry related  
400 genes expression dynamics of CMs and NCMs in both normal heart and HF patients. In normal  
401 heart, most of cell types of CMs and NCMs were detected high percentage of ACE2+ cells  
402 comparing with it in the lung, which indicates heart may be infected if exposed to SARS-CoV-  
403 2. Chen *et.al.* reported that the pericytes (with marker genes ABCC9 and KCNJ8), but not the  
404 cardiomyocyte were ACE2+ cells in normal hearts<sup>28</sup>. According to our scRNA-seq analysis,

405 most cell types in the normal human heart, including CMs, smooth muscle cells, endothelial,  
406 fibroblasts and immune cells have relatively high levels of ACE2 expression. They applied  
407 single nucleus RNA-seq to their normal heart samples, which capture much fewer transcripts  
408 than the SMART-seq using whole-cell as input. Considering the limitation of their technology,  
409 our scRNA-Seq data is more comprehensive and recapitulates the real state of cells.

410 In the presence of cardiac dysfunction, not only the proportion of ACE2+ cardiomyocytes,  
411 especially ventricular myocytes, was dramatically increased in HF patients, but also the  
412 expression level of ACE2+ cells are significantly enhanced in cardiomyocytes, especially the  
413 ventricular myocytes as well (Fig. 4B). In our study, we have done two kinds of comparison  
414 for each type of CMs: 1) DEGs between failing CMs and normal cells, 2) DEG between ACE2+  
415 CMs with ACE- CMs. Interestingly, following GSEA analysis ( GO and pathway) of DEGs  
416 for these two kinds of comparisons achieved consistent results, in which GO term/Pathway  
417 associated with virus infection and virus genes expression were positively enriched, but defense  
418 to virus, secretion of IFN and activation of immune system were negatively enriched in CMs  
419 (Fig. 3B,3C, 6A, 6B). Our results suggest that patients with heart dysfunction or HF may have  
420 a higher susceptibility to SARS-CoV-2 infection (Fig. 7A).

421 The natriuretic peptide system (NPS), including ANP and BNP play an important role in  
422 chronic heart failure by synergizing with the renin-angiotensin-aldosterone system (RAAS)  
423 and sympathetic nervous system (SNS)<sup>29</sup>. In the early stage of heart failure, NPs are released  
424 to promote diuresis, natriuresis and vasodilation, which is critical for the maintenance of  
425 intravascular volume homeostasis (Fig, 7B) <sup>21</sup>. Meanwhile, ACE2 opposes the molecular and  
426 cellular effects of Ang II by converting Ang II into Ang 1-7 which acts as a vasodilator and

427 exerts protective effects in the cardiovascular system as well (Fig, 7B)<sup>20</sup>. However, along with  
428 heart failure progresses, the release of functional and effective NPs is blocked, exhibited  
429 increasing NPs but ineffective levels in plasma, further result in the heart dysfunction<sup>30</sup>.  
430 Previous studies have established that failed CMs could secrete poorly active prohormones like  
431 pro-ANP and pro-BNP<sup>31</sup>. COVID-19 patients SARS-CoV-2 infection could cause a series of  
432 symptoms related to myocardial injury, including cardiac dysfunction. So, we speculate NPs  
433 may play an important role in virus infection and following heart injury.

434 Patients suffered heart dysfunction and secreting ineffective NPs including pro-ANP and  
435 pro-BNP may have different scenario. Our scRNA-seq analysis results indicate that patients  
436 with heart dysfunction or HF have more ACE2+ CMs and higher expression ACE2 and have  
437 a higher susceptibility to SARS-CoV-2 infection. It was reported that SARS-CoV led to down-  
438 regulation of ACE2 and then up-regulate its substrates Ang II, which caused more severe lung  
439 injury in mice<sup>32, 33</sup>. Similar reaction axis was found in SARS-CoV-2 between ACE2 and Ang  
440 II, and the accumulation of Ang II may further lead to vascular effectiveness in other organs  
441 such as lung and kidney<sup>34</sup>. Moreover, BNP as an early responsive gene to stress in the  
442 myocardium than ANP<sup>35</sup>, whose expression level was increased significantly when stimulated  
443 by Ang II in human<sup>36, 37</sup>. In our study, DEG between ACE2+ and ACE2- ventricular myocytes  
444 showed both BNP and ANP were top two genes up-regulated. We searched ENCODE database  
445 for transcription factor (TF) binding sites in promoter of ACE2, ANP and BNP. Among the top  
446 five TFs, they share top two TFs (AP1 and c-Jun), which imply that they are probably be co-  
447 regulated during HF. For Patients suffered heart dysfunction and secreting ineffective NPs, if  
448 their hearts are infected by SARS-CoV-2, they don't have enough effective NPs and Ang1-7

449 to preserve ejection fraction; so more heart cell damage and more ACE2+ cells will be expected,  
450 which in versa cause more heart cells being susceptibility to SARS-CoV-2 infection (Fig7C).  
451 Finally, ACE2, ineffective NP, virus and Ang II formed a positive feedback loop, which lead  
452 to severe outcome. In summary, there have two scenarios for COVID-19 patients with heart  
453 dysfunction: 1) For patients have normal level of effective NPs, they may benefit from  
454 protective effects of NPs and ACE2 negative feedback loop and have better prognosis (Fig.  
455 7B). 2) For patients have deficient level of effective NPs, a positive feedback loop may be  
456 formed with ACE2, ineffective NP, virus, which cause worse prognosis (Fig. 7C). Drug ACEI  
457 or ARBs can break this positive feedback loop by reducing Ang II. They maybe benefit from  
458 these kinds of drugs, including ACEI, ARBs and LCZ696/Entresto. Ratio of effective versus  
459 ineffective NPs may be the very important factor to make decision whether patients can take  
460 these drugs or not.

461

#### 462 **Supplementary material**

463 Supplementary material is available at European Heart Journal online.

#### 464 **Acknowledgements**

465 We thank Xinli Hu for helpful discussion and review of the manuscript. Also, we also want to  
466 thank Yuxi Sun, Teng Ma and Yawei Xu for helpful discussion.

#### 467 **Funding**

468 This study was supported by grants from National Natural Science Foundation of China (No.  
469 81770391 to Dachun Xu)

470 **Conflict of interest:** None of the authors have any relevant conflicts of interest to declare.

## 471 Reference

- 472 1. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y,  
473 Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B.  
474 Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *The Lancet*  
475 2020;**395**(10223):497–506.
- 476 2. COVID-19 Dashboard by the Center for Systems Science and Engineering(CSSE) at Johns Hopkins.
- 477 3. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, Qiu Y, Wang J, Liu Y, Wei Y, Xia Ja, Yu T, Zhang X,  
478 Zhang L. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in  
479 Wuhan, China: a descriptive study. *The Lancet* 2020;**395**(10223):507–513.
- 480 4. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y, Zhao Y, Li Y, Wang X,  
481 Peng Z. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected  
482 Pneumonia in Wuhan, China. *JAMA* 2020.
- 483 5. Shi S, Qin M, Shen B, Cai Y, Liu T, Yang F, Gong W, Liu X, Liang J, Zhao Q, Huang H, Yang B, Huang C.  
484 Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China.  
485 *JAMA cardiology* 2020.
- 486 6. Guo T, Fan Y, Chen M, Wu X, Zhang L, He T, Wang H, Wan J, Wang X, Lu Z. Cardiovascular Implications  
487 of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19). *JAMA cardiology* 2020.
- 488 7. Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, Wang W, Song H, Huang B, Zhu N, Bi Y, Ma X, Zhan F, Wang  
489 L, Hu T, Zhou H, Hu Z, Zhou W, Zhao L, Chen J, Meng Y, Wang J, Lin Y, Yuan J, Xie Z, Ma J, Liu WJ, Wang  
490 D, Xu W, Holmes EC, Gao GF, Wu G, Chen W, Shi W, Tan W. Genomic characterisation and epidemiology  
491 of 2019 novel coronavirus: implications for virus origins and receptor binding. *The Lancet*  
492 2020;**395**(10224):565–574.
- 493 8. Zhou P, Yang X-L, Wang X-G, Hu B, Zhang L, Zhang W, Si H-R, Zhu Y, Li B, Huang C-L, Chen H-D,  
494 Chen J, Luo Y, Guo H, Jiang R-D, Liu M-Q, Chen Y, Shen X-R, Wang X, Zheng X-S, Zhao K, Chen Q-J, Deng  
495 F, Liu L-L, Yan B, Zhan F-X, Wang Y-Y, Xiao G-F, Shi Z-L. A pneumonia outbreak associated with a new  
496 coronavirus of probable bat origin. *Nature* 2020;**579**(7798):270–273.
- 497 9. Zou X, Chen K, Zou J, Han P, Hao J, Han Z. Single-cell RNA-seq data analysis on the receptor ACE2  
498 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection.  
499 *Frontiers of medicine* 2020.
- 500 10. Qi F, Qian S, Zhang S, Zhang Z. Single cell RNA sequencing of 13 human tissues identify cell types  
501 and receptors of human coronaviruses. *Biochemical and biophysical research communications* 2020.
- 502 11. Xu X, Chen P, Wang J, Feng J, Zhou H, Li X, Zhong W, Hao P. Evolution of the novel coronavirus from  
503 the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission. *Science*  
504 *China. Life sciences* 2020;**63**(3):457–460.
- 505 12. He S, Wang L, Liu Y, Li Y, Chen H, Xu J, Peng W, Lin G, Wei P, Li B, Xia X, Wang D, BEI J-X, He X, Guo  
506 Z. *Single-cell transcriptome profiling an adult human cell atlas of 15 major organs*; 2020.
- 507 13. Patel VB, Zhong J-C, Grant MB, Oudit GY. Role of the ACE2/Angiotensin 1–7 Axis of the Renin-  
508 Angiotensin System in Heart Failure. *Circulation research* 2016;**118**(8):1313–1326.
- 509 14. Zheng Y-Y, Ma Y-T, Zhang J-Y, Xie X. COVID-19 and the cardiovascular system. *Nature reviews.*  
510 *Cardiology* 2020.
- 511 15. World Health Organization interim guidance.
- 512 16. Qiu X, Mao Q, Tang Y, Wang L, Chawla R, Pliner HA, Trapnell C. Reversed graph embedding resolves

- 513 complex single-cell trajectories. *Nat Methods* 2017;**14**(10):979-982.
- 514 17. Boerrigter G, Costello-Boerrigter LC, Burnett JC. Natriuretic peptides in the diagnosis and  
515 management of chronic heart failure. *Heart failure clinics* 2009;**5**(4):501-514.
- 516 18. Wang L, Yu P, Zhou B, Song J, Li Z, Zhang M, Guo G, Wang Y, Chen X, Han L, Hu S. Single-cell  
517 reconstruction of the adult human heart during heart failure and recovery reveals the cellular landscape  
518 underlying cardiac function. *Nature cell biology* 2020;**22**(1):108-119.
- 519 19. Lu ZQ, Sinha A, Sharma P, Kislinger T, Gramolini AO. Proteomic analysis of human fetal atria and  
520 ventricle. *Journal of proteome research* 2014;**13**(12):5869-5878.
- 521 20. Patel VB, Zhong JC, Grant MB, Oudit GY. Role of the ACE2/Angiotensin 1-7 Axis of the Renin-  
522 Angiotensin System in Heart Failure. *Circ Res* 2016;**118**(8):1313-26.
- 523 21. Kuhn M. Cardiac actions of atrial natriuretic peptide: new visions of an old friend. *Circ Res*  
524 2015;**116**(8):1278-80.
- 525 22. Linke WA, Hamdani N. Gigantic business: titin properties and function through thick and thin.  
526 *Circulation research* 2014;**114**(6):1052-1068.
- 527 23. Takimoto E. Cyclic GMP-dependent signaling in cardiac myocytes. *Circulation journal : official journal*  
528 *of the Japanese Circulation Society* 2012;**76**(8):1819-1825.
- 529 24. Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, Schiergens TS, Herrler G,  
530 Wu N-H, Nitsche A, Müller MA, Drosten C, Pöhlmann S. SARS-CoV-2 Cell Entry Depends on ACE2 and  
531 TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. *Cell* 2020.
- 532 25. Kawase M, Shirato K, van der Hoek L, Taguchi F, Matsuyama S. Simultaneous treatment of human  
533 bronchial epithelial cells with serine and cysteine protease inhibitors prevents severe acute respiratory  
534 syndrome coronavirus entry. *Journal of virology* 2012;**86**(12):6537-6545.
- 535 26. Moore BJB, June CH. Cytokine release syndrome in severe COVID-19. *Science (New York, N.Y.)* 2020.
- 536 27. Toschi V, Gallo R, Lettino M, Fallon JT, Gertz SD, Fernández-Ortiz A, Chesebro JH, Badimon L,  
537 Nemerson Y, Fuster V, Badimon JJ. Tissue factor modulates the thrombogenicity of human atherosclerotic  
538 plaques. *Circulation* 1997;**95**(3):594-599.
- 539 28. Chen L, Li X, Chen M, Feng Y, Xiong C. The ACE2 expression in human heart indicates new potential  
540 mechanism of heart injury among patients infected with SARS-CoV-2. *Cardiovascular research* 2020.
- 541 29. Diez J. Chronic heart failure as a state of reduced effectiveness of the natriuretic peptide system:  
542 implications for therapy. *Eur J Heart Fail* 2017;**19**(2):167-176.
- 543 30. Volpe M, Carnovali M, Mastromarino V. The natriuretic peptides system in the pathophysiology of  
544 heart failure: from molecular basis to treatment. *Clinical Science* 2015;**130**(2):57-77.
- 545 31. Niederkofler EE, Kiernan UA, O'Rear J, Menon S, Saghir S, Protter AA, Nelson RW, Schellenberger U.  
546 Detection of endogenous B-type natriuretic peptide at very low concentrations in patients with heart failure.  
547 *Circulation. Heart failure* 2008;**1**(4):258-264.
- 548 32. Kuba K, Imai Y, Rao S, Gao H, Guo F, Guan B, Huan Y, Yang P, Zhang Y, Deng W, Bao L, Zhang B, Liu  
549 G, Wang Z, Chappell M, Liu Y, Zheng D, Leibbrandt A, Wada T, Slutsky AS, Liu D, Qin C, Jiang C, Penninger  
550 JM. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. *Nat*  
551 *Med* 2005;**11**(8):875-9.
- 552 33. Acanfora D, Ciccone MM, Scicchitano P, Acanfora C, Casucci G. Nephilysin inhibitor-angiotensin II  
553 receptor blocker combination (sacubitril/valsartan): rationale for adoption in SARS-CoV-2 patients. *Eur*  
554 *Heart J Cardiovasc Pharmacother* 2020.
- 555 34. Muthiah Vaduganathan MD, M.P.H., Orly Vardeny, Pharm.D., Thomas Michel, M.D., Ph.D., , John J.V.  
556 McMurray MD, Marc A. Pfeffer, M.D., Ph.D., and Scott D. Solomon, M.D. Renin-Angiotensin-Aldosterone

557 System Inhibitors in Patients with Covid-19. The NEW ENGLAND JOURNAL of MEDICINE 2020;**382**:1653-  
558 1659.

559 35. Nakagawa O, Ogawa Y, Itoh H, Suga S, Komatsu Y, Kishimoto I, Nishino K, Yoshimasa T, Nakao K.  
560 Rapid transcriptional activation and early mRNA turnover of brain natriuretic peptide in cardiocyte  
561 hypertrophy. Evidence for brain natriuretic peptide as an "emergency" cardiac hormone against ventricular  
562 overload. J Clin Invest 1995;**96**(3):1280-7.

563 36. de Lemos JA, McGuire DK, Drazner MH. B-type natriuretic peptide in cardiovascular disease. The  
564 Lancet 2003;**362**(9380):316-322.

565 37. Holubarsch CJF. Gene Expression of Brain Natriuretic Peptide in Isolated Atrial and Ventricular Human  
566 Myocardium : Influence of Angiotensin II and Diastolic Fiber Length. Circulation 2000;**102**(25):3074-3079.

567

568

569

**Table 1. Comparison of COVID-19 patient characteristics between BNP groups.**

Parameters	Total (N=91)	BNP<100 (N=45)	BNP≥100 (N=46)	p value
Age, yrs	66 (55.5, 73.0)	62.0 (46.0, 69.0)	79.0 (63.5, 79.0)	<0.0001*
Male, n (%)	54 (59.3)	23 (51.1)	31 (67.4)	0.11
<b>Complete blood cell count, 10<sup>9</sup>/L</b>				
White blood cell	7.99 (4.59, 13.31)	6.28 (4.04, 8.38)	13.05 (6.76, 18.13)	<0.0001*
Neutrophil	6.6 (3.43, 12.32)	4.29 (2.74, 6.67)	11.88 (4.83, 16.93)	<0.0001*
Lymphocyte	0.71 (0.38, 1.09)	0.98 (0.62, 1.47)	0.50 (0.27, 0.78)	<0.0001*
<b>Liver and renal function</b>				
Alanine transaminase, U/L	30.0 (18.5, 52.5)	27.0 (19.0, 49.0)	32.0 (18.0, 64.0)	0.5783
Aspartate transaminase, U/L	37.0 (23.0, 55.0)	30.0 (20.0, 51.0)	41.5 (29.0, 64.0)	0.0299*
TBIL, µmol/L	14.1 (9.5, 21.7)	11.8 (9.1, 17.8)	15.2 (10.1, 24.4)	0.1216
Direct bilirubin, µmol/L	5.3 (3.4, 9.8)	4.1 (3.0, 6.5)	6.6 (4.0, 13.2)	0.0047*
Lactate dehydrogenase, U/L	315.0 (179.5, 470.5)	185.0 (154.0, 352.0)	407.0 (288.0, 599.0)	<0.0001*
eGFR, mL/(min*1.73m <sup>2</sup> )	105.6±47.0	121.1±41.6	86.5±44.5	0.0003*
Blood urea nitrogen, mmol/L	5.7 (3.9, 11.1)	4.5 (3.2, 5.8)	9.0 (5.2, 15.9)	<0.0001*
Uric acid, µmol/L	234.0 (183.5, 305.5)	235.0 (184.0, 305.0)	230.5 (182.0, 310.0)	0.9494
<b>Cardiac biomarker</b>				
Troponin-I, ng/mL	0.01 (0.01, 0.06)	0.01 (0.01, 0.01)	0.05 (0.03, 0.25)	<0.0001*
<b>Electrolytes</b>				
Potassium, mmol/L	4.04 (3.64, 4.40)	3.87 (3.56, 4.27)	4.19 (3.64, 4.70)	0.0354*
Sodium, mmol/L	139.0 (136.0, 142.0)	139.0 (135.0, 141.0)	139.0 (136.0, 145.0)	0.2992
Chloride, mmol/L	102.0 (98.5, 106.0)	103.0 (100.0, 106.0)	101.5 (98.0, 106.0)	0.6473
Calcium, mmol/L	2.03±0.18	2.09±0.16	1.97±0.18	0.0018*
<b>Coagulation profiles</b>				
Prothrombin time, s	13.4 (12.4, 14.9)	13.0 (12.0, 13.8)	13.9 (12.8, 16.7)	0.0030*
APTT, s	35.5 (31.8, 39.8)	35.1 (32.4, 38.9)	35.5 (30.7, 42.5)	0.6165
Fibrinogen, g/L	3.39 (2.31, 4.77)	3.39 (2.31, 5.09)	3.40 (2.35, 5.87)	0.8567
D-dimer, µg/mL	2.03 (1.22, 1.00)	1.37 (0.83, 1.99)	6.96 (3.25, 24.20)	<0.0001*
<b>Inflammatory biomarkers</b>				
Procalcitonin, ng/mL	0.45 (0.12, 1.12)	0.23 (0.04, 0.49)	1.01 (0.39, 3.51)	<0.0001*

570

571

hsCRP, mg/L	13.80 (5.74, 20.50)	6.09 (1.52, 15.86)	18.00 (13.45, 21.50)	<0.0001*
<b>Blood gas analysis</b>				
PaO <sub>2</sub> , mmHg	71.0 (57.8, 92.0)	78.5 (57.5, 104.5)	68.5 (56.5, 86.0)	0.4867
PaCO <sub>2</sub> , mmHg	41.0 (34.0, 48.8)	39.5 (33.5, 43.5)	42.5 (34.0, 57.9)	0.1589
Lactic acid, mmol/L	1.95 (1.40, 2.40)	1.80(1.30, 2.15)	2.00 (1.60, 2.75)	0.1634
BNP, pg/mL	92.0 (32.5, 299.5)	34.0 (15.0, 48.0)	299.5 (180.0, 548.0)	<0.0001*
Death, n (%)	32 (35.16)	5 (11.11)	27 (58.70)	<0.0001*

Continuous variables are presented as means±SD if conform normal distribution or

median with interquartile range if not. Categorical variables are presented as percentage


(%).

\* Significant p value (<0.05).

TBIL denotes total bilirubin, eGFR estimated glomerular filtration rate (calculated by

MDRD formula), APTT activated partial thromboplastin time, hsCRP high-sensitive C-

reactive protein, BNP B-type natriuretic peptide.




573

574 **Supplemental Figure. 1. Enrichment of biological pathway in different subsets from**  
 575 **comparison of HF patients and normal (related to Fig. 3)**

576

577 **A-F, GO analysis revealed that significant enrichment of biological pathway from comparison**  
 578 **of HF patients and normal in different subsets. A, CM2 and CM3 subsets. B, Smooth muscle**  
 579 **cells. C, endothelial cells. D, Granulocytes. E, NK-T cells/Monocytes. F, Fibroblasts.**




580

581 **Supplemental Figure 2. Distribution of virus-related genes in HF patients compared with**  
 582 **normal (related to Figure 5)**

583

584 **A**, Violin plots of the distribution of STOML2 related to the biogenesis and activity of  
 585 mitochondria. **B**, Violin plots of the distribution of CHMP5 related to virus infection. **C**, Violin  
 586 plots of the distribution of TMPRSS2 related to viral entry. **D**, UMAP of F3 in normal and HF  
 587 patients (left) and violin plots of the distribution of F3 (right). **E**, Expression level of ACE2  
 588 (red dots), F3 (green dots) in different subsets, overlapping is shown in the right panel, and the  
 589 co-expression is shown in yellow dots.



590

591 **Supplemental Figure 3. Characteristics of ACE2 positive ventricular and atrial myocytes**

592 **(related to Figure 6)**

593

594 **A**, Pathway analysis revealed the significant enrichment of biological pathways from

595 comparison of ACE2+ and ACE2- ventricular myocytes. **B**, Pathway analysis revealed the

596 significant enrichment of biological pathways from comparison of ACE2+ and ACE2- atrial


597 myocytes. **C**, Reactome analysis showing the up-regulated influenza infection and down-

598 regulated interferon-alpha\_beta signaling and interferon signaling in ventricular myocytes

599 comparison of ACE2+ and ACE2- cells. **D**, Reactome analysis showing the up-regulated

600 respiratory electron transport and down-regulated interferon gamma, interferon-alpha\_beta

601 signaling in atrial myocytes comparison of ACE2+ and ACE2- cells. The NES and false  
 602 discovery rate (FDR) were showed in panel.



603

604

605 Supplemental Figure 4. Enrichment of biological pathway in different subsets from

606 **comparison of ACE2 positive and negative cells (related to Figure 6)**

607

608 **A-E**, GO and pathway analysis revealed the significant enrichment of biological pathway from

609 comparison of ACE2<sup>+</sup> and ACE2<sup>-</sup> cells in different subsets. **A**, Smooth muscle cells. **B**,

610 endothelial cells. **C**, Granulocytes. **D**, NK-T cells/Monocytes. **E**, Fibroblasts.

611

612